Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin + irinotecan in pretreated advanced solid tumors
2024-515394-10-00Phase 2Completed
- Sponsor
- PharmaMar
- Start
- Aug 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of lurbinectedin and irinotecan in Nonhematologic neoplasms, glioblastoma (GBM), soft tissue sarcoma (STS) and 9 more (4 arms), sponsored by PharmaMar. Started Aug 2024; status: completed.
02
Drugs
lurbinectedinirinotecan
03
Conditions
Nonhematologic neoplasmsglioblastoma (GBM)soft tissue sarcoma (STS)endometrial cancer (EC)epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on 2024-515394-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515394-10-00.